Predictive Oncology, Inc.

As of August 14, 2018, Predictive Oncology, Inc. is considered overvalued and risky due to negative valuation ratios and a significant long-term decline of 94.26%, despite a recent year-to-date stock return of 20.39%.

As of August 14, 2018, Predictive Oncology, Inc. is considered overvalued and risky due to negative financial metrics, including a P/E ratio that is not applicable, a price-to-book value of -8.38, and an EV to EBITDA ratio of -0.61, along with significant underperformance compared to the S&P 500.

As of June 18, 2025, Predictive Oncology, Inc. is in a bearish trend, indicated by a bearish MACD, Bollinger Bands, moving averages, and underperformance against the S&P 500.

As of March 2022, the management team of Predictive Oncology, Inc. includes Dr. Carl Schwartz as President and CEO, along with Directors Mr. J. Engle, Mr. H. Gabriel, Dr. Daniel Handley, Ricardo Koenigsberger, and Mr. Timothy Krochuk.

Predictive Oncology, Inc. utilizes artificial intelligence for personalized medicine and drug discovery in the Pharmaceuticals & Biotechnology sector. As of March 2025, it has a market cap of $8.22 million, with net sales of $0 million and a net profit of -$2 million.

As of Jun 18, Predictive Oncology, Inc. has a market capitalization of 8.22 million, with recent net sales of 1.35 million and a net profit of -9.85 million. The company's shareholder's funds were -0.20 million, and total assets amounted to 4.97 million.